



RESEARCH ARTICLE

Frequencies New Delhi Metallo- β -Lactamase (NDM) in *Klebsiella pneumoniae* Isolates from Clinical Samples in Al-Basrah Governorate, Iraq

Intithar M. Mozan¹, Saad S. M. Al-Amara^{*2}

¹Microbiology laboratory, Basrah Teaching Hospital, Basrah Health directory, Iraq

²Department of Pathological Analyses, College of Science, University of Basrah, Iraq

ARTICLE INFORMATION

Article history:

Received: 20 July 2023

Revised: 27 August 2023

Accepted: 3 September 2023

Published: 24 September 2023

Keywords:

Metallo- β -lactamases (MBL), bla_{NDM}, *Klebsiella pneumoniae*

Corresponding author:

Saad S. M. Al-Amara

Email: saad.mahdi@uobasrah.edu.iq

Department of Pathological Analyses, College of Science, University of Basrah, Iraq

ABSTRACT

Background: Metallo- β -lactamases (MBL) genes are crucial for resistance to antibiotics, and early detection is essential for infection control and prevention of nosocomial outbreaks.

Methods: One hundred fifty clinical samples from Basrah hospitals were collected between October and December 2022 and categorized equally into 50 samples for each sputum, urine, and wound swab. *K. pneumoniae* isolates were identified morphologically and tested on MacConkey and blood agar. The *Klebsiella pneumoniae* chromogenic medium and Vitek[®]2 system was used as confirmation tests. Genomic DNA extracted from *K. pneumoniae* isolates using a commercial purification kit. The DNA extraction was amplified using PCR for 16S rDNA amplification *K. pneumoniae* isolates using a specific primer of approximately (130bp). *K. pneumoniae* carbapenemase (KPC) chromogenic agar and modified hodge test, according to CLSI were used to test the *K. pneumoniae* isolates for detect the ability of carbapenemase production. Plasmid DNA was extracted from *K. pneumoniae* isolates and plasmid DNA was amplified using PCR to detect the bla_{NDM} gene using a specific primer of approximately (621bp).

Results: From November to December 2022, one hundred fifty samples were investigated for bacterial growth, of which gave 82 (56%) were positive and 68 (45.4%) had negative results. Gram-positive bacteria were 28(34.1%), while Gram-negative bacteria were 54(64.9%), including *Klebsiella pneumoniae* 32(59.26%), *E. coli* 16 (29.63%), *Klebsiella spp.* 3 (5.56%), *Pseudomonas spp.* 2 (3.7%), and 1(1.85%) *Proteus spp.* All *K. pneumoniae* isolates showed mucoid pink, white, and purple appearances on MacConkey agar, blood agar, and *K. pneumoniae* chromogenic medium, respectively. The vitek[®]2 system showed 100% accuracy results in biochemical tests and *K. pneumoniae* medium. The PCR technology was used to diagnose gene 16S rDNA. The results showed that all (n = 32) *K. pneumoniae* isolates had a molecular weight of (130 bp) when compared with the standard molecular DNA ladder (200 bp). On the other side, the (n=32) *K. pneumoniae* isolates tested on *Klebsiella pneumoniae* carbapenemase chromogenic agar and modified Hodge test, 16 (50%) showed positive results and 16 (50%) showed negative results for carbapenemase production in both methods. On the other side PCR molecular diagnostics the bla_{NDM} gene results showed that all (n = 32) *K. pneumoniae* isolates revealed a molecular weight of (621 bp), when compared with the standard molecular DNA ladder (200 bp).

Conclusions: To select the best treatment and avoid losses time and money, use *Klebsiella pneumoniae* carbapenemase (KPC) chromogenic agar, modified Hodge test, and PCR techniques for daily antibiotic susceptibility testing in hospital and private clinical laboratories.

Copyright©2023, **Authors.** This open access article is distributed under the Creative Commons Attribution-Non Commercial 4.0 International (CC BY-NC-SA 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

CITATION: Mozan IM, Al-Amara SSM. Frequencies New Delhi Metallo- β -Lactamase (NDM) in *Klebsiella pneumoniae* Isolates from Clinical Samples in Al-Basrah Governorate, Iraq. *Sci. J. Med. Res.* 2023;7(27):15-18. DOI: 10.37623/sjomr.v07i27.03

INTRODUCTION

Klebsiella pneumoniae, an Enterobacteriaceae family opportunistic pathogen, causes nosocomial and community infections.¹ It affects healthy individuals and *often inhabits* the nose, throat, skin, and intestinal tract, but can also cause diseases like pneumonia, urinary tract infections, soft tissue infections, surgical wounds, and sepsis.² Due to the existence of carbapenem-resistant *Klebsiella pneumoniae* (CRKP), a multidrug-resistant strain of *K. pneumoniae*, is a serious public health concern on a global level.³ The misuse and overuse of carbapenems, despite their widespread usage to treat infections brought on by Enterobacteriaceae, has helped speed up the emergence of *K. pneumoniae* isolates that are resistant to these drugs.^{4,5} Carbapenem resistance is caused by genes encoding, the most common acquired metallo- β -lactamases (MBLs) include IMP (active on imipenem), VIM (Verona integron-encoded metallo- β -lactamase), SPM (Sao Paulo metallo- β -lactamase), GIM (German imipenemase), SIM (Seoul imipenemase), and NDM (New Delhi metallo-beta-lactamase) enzymes, altering the outer membrane protein (OMP) expression and efflux pumps.

Most resistance is due to carbapenemase production, which hydrolyzes various penicillins, carbapenems, cephalosporins, and aztreonams.⁶ MBL genes are found throughout many integrons containing MBL genes that are connected with plasmids or transposons across bacteria. MBL genes play a significant role in the occurrence and are critical for resistance to β -lactam antibiotics in community and hospital settings. Early diagnosis of MBL-producing organisms is critical for infection control and nosocomial outbreak prevention. This study aimed to look for NDM genes in carbapenem-resistant *K. pneumoniae* isolates from different clinical samples from the Al-Basrah governorate, Iraq.

MATERIALS AND METHODS

Collection of specimens

A total of 150 clinical samples from Basrah hospitals, including Basrah Teaching Hospital Al-Sadder Teaching Hospital, were collected between October and December 2022 and categorized equally into 50 samples for each sputum, urine, and wound swab sample.

Isolation and identification

The *K. pneumoniae* isolates were identified morphologically on MacConkey and blood agar.^{7,8} The *K. pneumoniae* chromogenic medium and Vitek®2 system was used as confirmation tests.⁹

DNA extraction

Genomic DNA extracted from *K. pneumoniae* isolates using a commercial purification kit (Presto™ Mining DNA Bacteria, Geneaid, USA) using a manufacturer's protocol.

Detection of 16S rDNA

The DNA extraction was amplified using PCR for 16S rDNA amplification *K. pneumoniae* isolates using a specific primer

of approximately (130bp).^{10, 11} The resulting PCR product was compared with a standard molecular DNA ladder(2000 bp).

Phenotypic carbapenemase production test

Klebsiella pneumoniae chromogenic medium

The *K. pneumoniae* carbapenemase (KPC) chromogenic agar was used to test the *K. pneumoniae* isolates to detect the ability for carbapenemase production using a manufacturer's protocol.

Modified Hodge Test (MHT)

According to CLSI,¹² the MHT test was performed on all *K. pneumoniae* isolates.

Plasmid DNA extraction

Plasmid DNA that was extracted from *K. pneumoniae* isolates according to (Pure Yield™ Plasmid Miniprep System, Promega, USA).

Amplified the plasmids bla_{NDM}

The extracted plasmid DNA was amplified using PCR to detect the *bla*_{NDM} gene, using a specific primer approximately (621bp),¹³ The resulting PCR product was compared with a standard molecular DNA ladder(2000 bp).

RESULTS

From November to December 2022, 150 samples were collected and analyzed for bacterial growth. 82 (56%) were positive, while 68 (45.4%) had negative results. Biochemical tests, the Vitek®2 system, and PCR techniques were used. Gram-positive bacteria were 28 (34.1%), while Gram-negative bacteria were 54 (64.9%), including *Klebsiella pneumoniae* 32(59.26%), *E. coli* 16(29.63%), *Klebsiella* spp. 3(5.56%), *Pseudomonas* spp. 2(3.7%), and 1(1.85%) *Proteus* spp. Figure 1. All (n=32) *K. pneumoniae* isolate colonies showed mucoid pink, white, and purple-colored appearances on MacConkey agar, blood agar, and *Klebsiella pneumoniae* chromogenic medium, respectively, the result of vitek®2 system showed the all (n=32) *K. pneumoniae* isolates achieved 100% accuracy in biochemical test and *Klebsiella pneumoniae* medium. The results of molecular diagnostics using PCR technology, depending on the diagnostic gene 16S rDNA, showed that all (n=32) *K. pneumoniae* isolates revealed a molecular weight of 130 bp at a percentage (100%) Figure 2. On the other side, the (n=32) *K. pneumoniae* isolates tested on *K. pneumoniae* carbapenemase (KPC) chromogenic agar and the modified Hodge test (MHT) method was used to detect carbapenem-resistant, out of (n=32) *K. pneumoniae* isolates, 16 (50%) showed positive results and 50 (50%) gave negative results for carbapenemase production in both methods Figures 3 and 4, respectively. On the other hand, the results of molecular diagnostics using PCR technology, depending on the diagnostic the *bla*_{NDM} gene showed that all (n=32) *K. pneumoniae* isolates revealed a molecular weight of 621bp at a percentage (100%), when compared with the standard molecular DNA ladder (200bp) Figure 5.




Figure 1: The frequency of gram-negative bacterial Isolates




Figure 2: PCR Amplified Products of 16S rDNA. Lane L:(2000 bp DNA ladder), Lane:(no. 1-7) 16S rDNA Band of *K. pneumoniae* Isolates using 1.5% agarose gel, 70V, 45 minutes.




Figure 3: The Results of *K. pneumoniae* isolates Positive and Negative Results for Carbapenemase by Using the *K. pneumoniae* Carbapenemase (KPC) Chromogenic Agar.




Figure 4: The Results of *K. pneumoniae* Isolates Positive and Negative Results for Carbapenemase by Using the Modified Hodge test (MHT).




Figure 5: Shows agarose electrophoresis patterns of *bla_{NDM}* gene PCR amplified products, using 1.5% agarose gel at 70V for 45 minutes.

DISCUSSION

This study reveals a lower prevalence rate of *K. pneumoniae* isolates 32(59.26%) compared to previous studies in Erbil (95.45%),¹⁴ Hilla hospitals (22%),¹⁵ Iran (25%),¹⁶ China (13.3,¹⁷ and Saudi Arabia Hospital (14.7%).¹⁸ The increasing isolation rate of *K. pneumoniae* has been observed in China, with a peak in 2020. The study found that *K. pneumoniae* infection was the predominant organism in urine samples 13 (26%), followed by sputum 11 (22%), and wound swabs 8 (16%).¹⁸ This differs from previous studies,¹⁹ which reported 18(36%) *K pneumoniae* isolated from sputum, 16(32%) from blood, 9(18%) from urine, and 7(14%) from wound swabs. *K. pneumoniae* is the second most common cause of healthcare-associated UTIs.²⁰

On other hand, *K. pneumoniae* isolate have also showed the highest prevalence in urine sample frequency in urine samples, consistent with previous studies in Baghdad (20%).²¹ Egypt (50%),²² and Duhok City (66.2%)²³. *K. pneumoniae* is a common cause of hospital-acquired pneumonia, with 11(22%) of isolates in the current study from sputum. It is a causative agent in severe infections like surgical-wound infections and septicemia and is associated with ventilator-associated pneumoniae.²⁴⁻²⁶ *K. pneumoniae* colonizes mucosal surfaces, leading to hospital-acquired pneumonia.²⁷ Genotyping is crucial for identifying *K. pneumoniae* cases and tracking infection spread. Genotypic characterization methods are more accurate due to their adaptability to growth conditions, environmental factors, and temperature.²⁸ 16S rDNA diagnosis is superior to biochemical and phenotypic methods due to its gene presence.²⁹

Klebsiella pneumoniae carbapenemase (KPC) chromogenic agar is a reliable method for rapid laboratory detection of carbapenem-resistant.³⁰ Results show that out of 32 *K. pneumoniae* isolates, 16 (50%) showed positive results and 16 (50%) showed negative results for carbapenemase production. The MHC test is recommended by CLSI¹² for detecting carbapenemase production.^{31,32} It is sensitive and specific for *K. pneumoniae* carbapenemases type. Studies of³³ show that (52.17%) of isolates give positive results for MHT, while the study of³² and³⁴ show only (17%) and (24%) positive results, respectively. Modified Hodge test detects carbapenemases and New Delhi metallo-β-lactamase (NDM), but its diagnosis depends on PCR. A study³⁵ in Nigeria found *K. pneumoniae* isolates positive for carbapenemase production on modified Hodge but negative for *bla_{KPC}* gene on PCR, possibly due to other carbapenemase-producing genes. In current study the results were showed, out of (n=32) *K. pneumoniae* isolates, the 16 (50%) isolates gave positive results and the 16 (50%) isolates gave negative results for production of carbapenemase. MHT can be a very useful screening test to suspect such cases for epidemiological purpose.³²

ACKNOWLEDGEMENTS

The Department of Biology, College of Science, University of Basrah, Iraq, provided support for the study.

REFERENCES

- Li, L., Ma, J., Cheng, P., Li, M., Yu, Z., Song, X. & Wang, Z. (2023). Roles of two-component regulatory systems in *Klebsiella pneumoniae*: Regulation of virulence, antibiotic resistance, and stress responses. *Microbiological Research*, 127374.]
- Dong, N., Yang, X., Chan, E. W. C., Zhang, R., & Chen, S. (2022). *Klebsiella* species: Taxonomy, hypervirulence and multidrug resistance. *EBioMedicine*, 79, 103998.]
- Li, Y., Kumar, S., Zhang, L., & Wu, H. (2022). *Klebsiella pneumoniae* and Its Antibiotic Resistance: A Bibliometric Analysis. *BioMed research international*, 2022, 1668789.
- Fasciana, T., Gentile, B., Aquilina, M., Ciammaruconi, A., Mascarella, C., Anselmo, A., Fortunato, A., Fillo, S., Petralito, G., Lista, F. and Giammanco, A. (2019). Co-existence of virulence factors and antibiotic resistance in new *Klebsiella pneumoniae* clones emerging in south of Italy. *BMC Infect. Dise.* 19(928): 1-10.
- Reyes, J., Aguilar, A. C., & Caicedo, A. (2019). Carbapenem-Resistant *Klebsiella pneumoniae*: Microbiology Key Points for Clinical Practice. *International journal of general medicine*, 12, 437–446.
- Aurilio, C., Sansone, P., Barbarisi, M., Pota, V., Giaccari, L. G., Coppolino, F., ... & Pace, M. C. (2022). Mechanisms of action of carbapenem resistance. *Antibiotics*, 11(3), 421.]
- Holt, J.J., Krieg, N.R., Sneath, B.H.A., Staley, J.T. and Williams, S.T. (1994). *Bergey's manual determinative bacteriology*. 9th Ed. Williams and Wilken, Baltimore, PP.175-248.
- Harly, J.P. & Prescott, L.M.(2002). *Laboratory Exercises in microbiology*. 5th Edition, The McGraw -Hill Companies, Inc., New York.
- Grams, I., Grams, L., Litre Part, A., and Part, B. *Salmonella Differential Agar/Modified (Twin pack)(RajHans Medium)*. HiCrome™, 16.
- Podschun, R., & Ullmann, U. (1998). *Klebsiella spp.* as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clinical microbiology reviews*, 11(4), 589-603.]
- Osman, K. M., Hassan, H. M., Orabi, A., & Abdelhafez, A. S. (2014). Phenotypic, antimicrobial susceptibility profile and virulence factors of *Klebsiella pneumoniae* isolated from buffalo and cow mastitic milk. *Pathogens and global health*, 108(4), 191–199.
- Clinical and Laboratory Standards Institute (CLSI)*. (2020). *Performance Standards for Laboratory Antimicrobial Testing*, 30th ed. **Wayne, Pennsylvania, USA**.
- Mushi, M. F., Mshana, S. E., Imirzalioglu, C., and Bwanga, F. (2014). Carbapenemase genes among multidrug resistant gram negative clinical isolates from a tertiary hospital in Mwanza, Tanzania. *BioMed research international*, 2014.
- Ali, F. A., and Ismael, R. M. (2017). Dissemination of *Klebsiella pneumoniae* and *Klebsiella oxytoca* Harboring bla TEM genes isolated from different clinical samples in Erbil City. *Diyala Journal of Medicine*, 12(2), 40-51.
- Abbas, F.M. and Jarallah, E.M. (2017a). Detection of OXA-23 among carbapenem resistant clinical isolates of *Klebsiella pneumoniae* in Hilla. *J. of Babylon University/Pure and Applied Sci.*, 2(25):435-440.
- Mansury, D., Motamedifar, M., Sarvari, J., Shirazi, B., & Khaledi, A. (2016). Antibiotic susceptibility pattern and identification of extended spectrum β -lactamases (ESBLs) in clinical isolates of *Klebsiella pneumoniae* from Shiraz, Iran. *Iranian journal of microbiology*, 8(1), 55.
- Effah, C. Y., Sun, T., Liu, S., & Wu, Y. (2020). *Klebsiella pneumoniae*: an increasing threat to public health. *Annals of clinical microbiology and antimicrobials*, 19(1), 1.
- Jalal, N. A., Al-Ghamdi, A. M., Momenah, A. M., Ashgar, S. S., Bantun, F., Bahwerth, F. S. & Faidah, H. (2023). Prevalence and Antibigram Pattern of *Klebsiella pneumoniae* in a Tertiary Care Hospital in Makkah, Saudi Arabia: An 11-Year Experience. *Antibiotics*, 12(1), 164.
- Elsaid, E. M., Ahmed, O. I., Abdo, A. M., & Abdel Salam, S. A. (2023). Antimicrobial and antibiofilm effect of silver nanoparticles on clinical isolates of multidrug resistant *Klebsiella Pneumoniae*. *Microbes and Infectious Diseases*, 4(2), 542-554.
- Caneiras, C., Lito, L., Melo-Cristino, J., & Duarte, A. (2019). Community- and Hospital-Acquired *Klebsiella pneumoniae* Urinary Tract Infections in Portugal: Virulence and Antibiotic Resistance. *Microorganisms*, 7(5), 138.
- Al-Musawi, A.M.A. (2018). Genotypic and phenotypic typing of clinical *Klebsiella pneumoniae* local isolates. M.Sc. Thesis. College of Science, Al-Mustansiriyah University.
- Taha, M. S., Hagra, M. M., Shalaby, M. M., Zamzam, Y. A., Elkolaly, R. M., Abdelwahab, M. A., & Maxwell, S. Y. (2023). Genotypic Characterization of Carbapenem-Resistant *Klebsiella pneumoniae* Isolated from an Egyptian University Hospital. *Pathogens (Basel, Switzerland)*, 12(1), 121.
- Naqid, I. A., Hussein, N. R., Balatay, A. A., Saeed, K. A., & Ahmed, H. A. (2020). The antimicrobial resistance pattern of *Klebsiella pneumoniae* isolated from the clinical specimens in Duhok City in Kurdistan Region of Iraq. *Journal of Kermanshah University of Medical Sciences*, 24(2).
- Li, B.; Zhao, Y.; Liu, C.; Chen, Z. and Zhou, D. (2014). Molecular pathogenesis of *Klebsiella pneumoniae*. *Future Microbiol.* 9(9):1071–081.
- Tai, A. Y.; Stuart, R.L.; Sidjabat, H. E.; Lemoh, C. N.; Rogers, B. A. and Graham, M. (2015). Local acquisition and nosocomial transmission of *Klebsiella pneumoniae* harbouring the bla_{NDM-1} gene in Australia. *Med. J. Aust.* 202(5):270–72.
- Seifi, K., Kazemian, H., Heidari, H., Rezagholizadeh, F., Saeed, Y., Shirvani, F., & Houri, H. (2016). Evaluation of biofilm formation among *Klebsiella pneumoniae* isolates and molecular characterization by ERIC-PCR. *Jundishapur journal of microbiology*, 9(1).
- Ashurst, J.V. and Dawson, A. 2019. *StatPearls. Treasure Island (FL) . Klebsiella Pneumonia*. 81(5):112-113
- Cheng, F., Li, Z., Lan, S., Liu, W., Li, X., Zhou, Z., Song, Z., Wu, J., Zhang, M., & Shan, W. (2018). Characterization of *Klebsiella pneumoniae* associated with cattle infections in southwest China using multi-locus sequence typing (MLST), antibiotic resistance and virulence-associated gene profile analysis. *Braz. J. Microbiol.* 49 (1): 93–100.
- Clarridge, J. E. (2004). Impact of 16S rDNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases. *CMR*. 17(4):840-862.
- Samra, Z., Bahar, J., Madar-Shapiro, L., Aziz, N., Israel, S., & Bishara, J. (2008). Evaluation of chrom agar KPC for rapid detection of carbapenem-resistant Enterobacteriaceae. *Journal of clinical microbiology*, 46(9), 3110-3111.
- Jean B. Patel, Franklin R. JA. M100-S24: (2014) Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement.
- Anjad, A., Mirza, I. A., Abbasi, S. A., Farwa, U., Malik, N., & Zia, F. (2011). Modified Hodge test: A simple and effective test for detection of carbapenemase production. *Iranian journal of microbiology*, 3(4), 189.
- Khalil, M. A., Elgami, A., & El-Mowafy, M. (2017). Emergence of multidrug-resistant New Delhi metallo- β -lactamase-1-producing *Klebsiella pneumoniae* in Egypt. *Microbial Drug Resistance*, 23(4), 480-487.
- Aseem, R., Shenoy, S., Mala, S. S., Baliga, S., & Ashish, A. (2016). Approach to carbapenemase detection in *Klebsiella pneumoniae* in routine diagnostic laboratories. *Journal of clinical and diagnostic research: JCDR*, 10(12), DC24.
- Aghanya, I. N., Akujobi, C. N., Ushie, S. N., Ubajaka, C. F., Ajuba, I. M., Ezeama, C. J., ... & Chigbo, C. G. (2021). Detection of Carbapenemase-producing *Klebsiella pneumoniae* isolated from Environmental Sources in a Tertiary Health Institution in Nigeria.